a2 National Symposium

Anna Barnacka, PhD, is the founder and CEO of MindMics, where she leads the development and commercialization of an AI-powered, in-ear infrasonic hemodynography platform for continuous cardiovascular monitoring using consumer in-ear devices. Trained as an astrophysicist, she holds PhDs in physics and astronomy and was a NASA Einstein Fellow at Harvard before transitioning into biomedical innovation. Beyond health technology, she is also a director of the Multiverse Concert Series and served as the scientific lead for Black Hole Symphony, interdisciplinary projects that bridge science, art, and music to make complex scientific ideas accessible to all.

Keith Camhi, MBA, MS, invests in and advises talented entrepreneurs at Techstars, where he is the managing director of the Techstars Healthcare Accelerator powered by Permanente Medicine in Washington, D.C. During his 7-year tenure at Techstars, he has led the global accelerator investment team, run accelerator programs with other prominent partners including Melinda Gates's Pivotal Ventures (Future of Longevity), Samvid Ventures (Economic Mobility), and J.P. Morgan (in Washington, D.C. and New York City), and has invested in nearly 80 startups.

Prior to Techstars, Camhi founded and scaled FitLinxx (securing over $50M in venture capital and reaching #20 on the Deloitte Fast 500) and Great Play (three-time Entrepreneur Franchise 500 honoree), and he served as an entrepreneur-in-residence for two funds focused on healthcare and early childhood development. He holds degrees from Cornell University and the Massachusetts Institute of Technology, and has been awarded multiple patents in sensor and machine vision technology.

Tracy Killoren Chadwell, JD, is the founding partner of 1843 Capital, a venture capital fund focused on early-stage technology companies solving for the 100+ year health span. Through her work she hopes to change the way we view and experience aging. Notable investments include Beautycounter (exited: $1B), MIDI Health, Function Health, HopSkipDrive, and May Mobility. She has been featured on Bloomberg Markets and served as a speaker for the Milken Institute Global Conference, SXSW, MIT and TedxNYIT. In 2021, Chadwell was named to Forbes magazine’s inaugural 50 Over 50 list and in 2019 to Entrepreneur magazine’s 100 Powerful Women list. Formerly, she was a partner at Baker Capital, a $1 billion growth capital fund, and a VP at Robertson Stephens; she is also a Kauffman Fellow.

Chadwell began her career at Nagashima and Ohno in Tokyo, Japan. She is a current board member for Recuro Health, Haven Headache, and Emerge Health; a board observer for Corsha; and an advisory board member for Millennium New Horizons technology venture fund. She also was a former board member of the YWCA of Chicago and treasurer and board member of the Belle Haven Land Company.

Tony Chan, JD, is global co-leader of Orrick’s Life Sciences & HealthTech Sector. His practice focuses on representing private equity and strategic clients in the life sciences, healthcare, investment management and tech sectors on complex domestic and cross-border corporate transactions. Chan regularly advises on mergers and acquisitions (M&A), private equity, growth equity, and venture capital transactions, as well as on corporate governance, joint ventures, and corporate finance matters. He has been recognized for his life sciences and M&A work by a number of notable publications, including The Legal 500 US, Law360, IFLR1000, and Legal Media Group. In particular, Law360 highlighted his work in navigating the complex life sciences industry and key partnership negotiations between biotechnology and drug companies.

In addition, Chan sustains an active pro bono practice, serving as counsel to nonprofit organizations such as Aequitas, APAI Vote, Chefs Stopping Asian American Hate, Rebuilding Together Philadelphia, the Philadelphia Film Society, and the Harvard Asian American Alumni Alliance. Chan also serves as an adjunct professor at Georgetown Law School where he has taught Takeovers, Mergers, and Acquisitions since 2015.

‍

Rama Chellappa, PhD, is a Bloomberg Distinguished Professor in the Departments of Electrical and Computer Engineering and Biomedical Engineering at Johns Hopkins University (JHU). He serves as co-principal investigator for JH AITC and is the former interim director of the JHU Data Science and AI Institute. He is also a member of JHU’s Center for Imaging Science, Center for Language and Speech Processing, Institute for Assured Autonomy, and Mathematical Institute for Data Science.

Dr. Chellappa's work in computer vision, pattern recognition, and machine learning have had a profound impact on areas including biometrics, smart cars, forensics, and 2D and 3D modeling of faces, objects, and terrain, while his work in motion capturing and imaging shows promise for future use in health care and medicine. He is the author of Can We Trust AI?, a member of the National Academy of Engineering, and a Life Fellow of the Institute of Electrical and Electronics Engineers (IEEE). He completed his PhD in electrical engineering at Purdue University.

‍

I. Glenn Cohen, JD, is the deputy dean and James A. Attwood and Leslie Williams Professor of Law at Harvard Law School and serves as faculty director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. He is one of the world’s leading experts on the intersection of bioethics and the law, as well as health law. He is an elected member of the National Academy of Medicine and served as a faculty scholar for the Greenwall Foundation. He has spoken to NATO on biotechnology and human enhancement, addressed the OECD and members of the U.S. and the Korean Congress on medical AI policy, and advised former U.S. Vice President Kamala Harris on reproductive rights. He has provided bioethical advising and consulting to some of the largest healthcare companies in the world including Bayer, Otsuka, and Illumina. He has given grand rounds and lectured to medical and industry conferences across the world.

Cohen is the author of more than 300 articles and the author, co-author, editor, or co-editor of more than 20 books. His work has appeared in leading law, medicine, and science journals and has been frequently covered by or appeared in media venues such as PBS, NPR, ABC, NBC, CBS, CNN, The New York Times, The Washington Post, and The Boston Globe. He received his JD from Harvard Law School.

George Demiris, PhD, is the Penn Integrates Knowledge Mary Alice Bennett University Professor at the University of Pennsylvania, with joint faculty appointments in Penn Nursing’s Department of Biobehavioral Health Sciences and the Perelman School of Medicine’s Department of Biostatistics, Epidemiology, and Informatics. He also serves as associate dean for research and innovation at Penn Nursing and as co-principal investigator for PennAITech.

Dr. Demiris’s research focuses on the use of information technology to support older adults and their family caregivers and explore innovative solutions to promote independent aging and patient and family engagement. He is a co-founder of the Hospice Caregiver Research Network, an initiative led by researchers from various academic disciplines committed to designing and testing interventions to support family caregivers of patients at the end of life. Another area of his research includes the use of behavioral sensing, smart home, and Internet of Things technologies to promote independence for community-dwelling older adults and their families. He leads the Penn Community Collaboratory for Co-Creation (Penn4C).

‍

Luigi Ferrucci, MD, PhD, is a geriatrician and epidemiologist whose work centers on uncovering the biological mechanisms that drive physical and cognitive decline in older adults. As scientific director of the National Institute on Aging (NIA) since 2011, he has advanced interdisciplinary research that integrates neuroimaging, physiology, genomics, and emerging AI-enabled methods to better understand the aging process.

Dr. Ferrucci’s career spans decades of pioneering research, including leadership of the Longitudinal Studies Section at NIA and the Baltimore Longitudinal Study of Aging, as well as major contributions in the design of many epidemiological studies conducted in the United States and Europe.

Deepak Ganesan, PhD, is a professor and Manning Fellow in the Department of Computer Science at UMass Amherst, and co-principal investigator for MassAITC. He also served as director of the Center for Personalized Health Monitoring (CPHM) at UMass Amherst from 2019–2024 and led its efforts toward end-to-end design of new health sensors from prototyping and fabrication to mobile health (mHealth) applications. He also served as the sensors-to-information thrust lead for the Mobile Data to Knowledge (MD2K) center funded by the National Institutes of Health.

Dr. Ganesan received his PhD in computer science from UCLA in 2004. He received the NSF CAREER Award in 2006, the IBM Faculty Award in 2008, and the UC3M-Santander Chair of Excellence in 2019. He was selected as a UMass Junior Faculty Fellow in 2008, and a UMass Lilly Teaching Fellow in 2009. He has served as program co-chair for ACM Mobicom 2024, MobiSys 2017, ACM SenSys 2010, and IEEE SECON 2013. His work has been recognized by ACM SIGMOBILE and ACM Research Highlights, a Test of Time Award at SenSys 2022, and best paper nominations or awards at various top conferences in computer science including ACM MobiSys, Mobicom, CHI, Ubicomp and IEEE SECON. He is an ACM Fellow.

Vadim Gladyshev, PhD, is a professor of medicine at Harvard Medical School and director of the Center for Redox Medicine at Brigham and Women’s Hospital. Dr. Gladyshev’s lab focuses on studying aging, rejuvenation, and lifespan control using a combination of experimental and computational approaches. He has published more than 400 articles. Dr. Gladyshev is the recipient of NIH Pioneer, Transformative, and Eureka awards and is an elected member of the National Academy of Sciences.

‍

Todd Haim, PhD, serves as senior advisor on biomedical innovation at the National Institute on Aging (NIA) and directs the NIA Office of Strategic Extramural Programs. He oversees approximately $150 million in annual seed funding that supports startups advancing cutting-edge technologies in aging, including AI-driven tools, digital health solutions, and next-generation biomedical innovations. Dr. Haim leads a team dedicated to strengthening NIA’s training, career development, and small business programs, expanding resources that help innovators translate scientific discoveries into real-world impact.

Before joining NIA, Dr. Haim served as program director at the National Cancer Institute’s SBIR Development Center and held roles at the National Academy of Sciences and Pfizer. He earned his PhD in biomedical research from the Albert Einstein College of Medicine and a technology commercialization certificate from the Johns Hopkins Carey Business School. Dr. Haim’s work has been recognized nationally through multiple awards, including the 2024 Champion of Small Business Commercialization Award and several NIH Director’s Awards.

‍

Katherine Hill Ritchie, MBA, is the senior director of venture funds at TEDCO, the state of Maryland’s venture capital fund that provides funding, resources, and connections for early-stage technology and life sciences companies in Maryland. Hill Ritchie has more than 20 years of finance and investment experience. She founded Private Capital Investments, LLC where she has worked internally and as an advisor to eight family offices and four billionaires.

Hill Ritchie serves as director and board member for Nottingham Spirk Family Office, and her past roles include: Simon Group Holdings, Eden Capital, PEX Global, and Wedge Alternatives. She is an early-stage angel investor, a member of Citrine Angels, and on the investment committee for University Impact, a social impact venture capital fund. Hill Ritchie is an advisor to several startups, with a focus on female and diverse founders, technology, medtech, consumer, and impact related early-stage venture companies. She received her MBA from Fordham University and her BS in psychology from the University of Maryland. She has also been recognized for her work within the family office industry, receiving the Lifetime Achievement Award from the Global Family Office Investment Summit. Her board member activities include: chair of the ACG New York Family Office Committee, board member of ACG NY, and Family Office Advisory Board of TriState Capital.

Ken Honeycutt is the director of Samsung Health at Samsung Electronics, where he leads the development and implementation of innovative digital health solutions to enhance the quality and accessibility of healthcare for millions of users.

Before joining Samsung Health, Honeycutt held roles in innovation and strategy for some of the largest healthcare vendors and providers in the United States, including Cardinal Health, McKesson, Cerner, the University of Pittsburgh Medical Center (UPMC), and IBM. He has also contributed to multiple patents and publications in the field of healthcare technology.

‍

Winn Hong, MBA, MS, is the North America venture manager at Nokia Ventures and the co-founder, president, and CEO of Mesencyte Inc. With over 18 years of experience in high-tech innovation, entrepreneurship, and leadership, he has successfully guided ventures across biotechnology, medical devices, alternative fuel, and digital technology. A fellow of the American Institute for Medical and Biological Engineering, he has held key roles including deputy executive director at the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California and senior technology strategist at UCLA’s Institute for Technology Advancement.

Earlier in his career, Hong worked at NASA’s Jet Propulsion Laboratory, contributing to the design and testing of advanced sensors for military, medical, and space applications. He later served as COO of Sega.com Inc. and Sega.com Ltd. (publicly traded on the Hong Kong Stock Exchange) and principal at Convergent Ventures, managing early-stage investments in life sciences and technology. He holds an MBA from the University of Chicago as well as an MS in mechanical engineering and a BS in aerospace engineering, both from UCLA.

Omer Imtiazuddin, MBA, is managing director of the Social Impact Funds at the American Heart Association (AHA) Ventures. A seasoned expert in impact investing, social entrepreneurship and global health, Imtiazuddin has spent over 25 years in both private and public sectors in the United States and around the world. Over 100 million people have been impacted through the work of his portfolio companies. Prior to joining the American Heart Association, he served as managing director of Finca Ventures, an early-stage global impact investing fund focusing on agriculture, global health, and financial inclusion that reached over 15 million people. He also led Innovative Finance for the Global Health Bureau at the United Stata Agency for International Development (USAID).

Frequently cited in mainstream media, Imtiazuddin has lectured at Wharton, Duke, and MIT Business Schools and advised on global initiatives including the USAID COVID-19 Task Force and the World Bank’s High Level Taskforce on Innovative International Financing for Health Systems. He holds an MBA from the Wharton School at the University of Pennsylvania and a BA from Yale University.

Anand Iyer, PhD, MBA, is the chief AI officer at Welldoc. Technology's highest purpose in healthcare is to elevate the human experience. This mission is deeply personal to Dr. Iyer, who lives with type 2 diabetes. At Welldoc, he leads the company’s AI and data intelligence strategy, crafting the next generation of health tech with more predictive, adaptive, and personal capabilities. He ensures Welldoc’s innovation is scientifically rigorous, ethical, and focused on empowering individual health journeys.

An innovator and respected global thought leader, Dr. Iyer pioneered BlueStar®, the first FDA-cleared digital therapeutic. Always on a quest to learn, he regularly connects with industry leaders across healthcare, tech, and academia. His proven ability to evolve and pivot is the ultimate proof that curiosity never stands still and is the engine for rethinking healthcare.

Jason Karlawish, MD, is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania, where he also serves as co-director of the Penn Memory Center and co-principal investigator and Clinical Translation and Validation Core co-lead for PennAITech. Dr. Karlawish is a physician and writer who researches and writes about issues at the intersections of bioethics, aging, and the neurosciences. He is the author of The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It and the novel Open Wound: The Tragic Obsession of Dr. William Beaumont. His essays have been published in The Wall Street Journal, The New York Times, Forbes, The Hill, The Los Angeles Times, The Philadelphia Inquirer, STAT, and The Washington Post. He is the producer of The Age of Aging, a podcast that examines how to live well with an aging brain.

Dr. Karlawish serves on the Pennsylvania Advisory Council on Elder Justice in the Courts; AARP’s Global Council on Brain Health; the Board of Directors for The Greenwall Foundation, a grant making foundation dedicated to expanding bioethics knowledge to improve clinical, biomedical, and public health decision-making, policy, and practice; and for Play On! Philly, a nonprofit providing orchestral music education for underserved children throughout Philadelphia.

‍

Nate Kline is The Wellness VC, a notably experienced executive, investor, and entrepreneur (four-time founder; Inc. 5000 honoree), boasting a multifaceted institutional finance career spanning more than two decades and a six-continent network. As an expert strategist and award-winning visionary, he’s added value across every business sector, company size, and stage, from fledgling startups to multinational conglomerates. Cistern Capital is a product of his personal passion for health and dedication to nurturing early-stage founders.

Prior to Cistern, Kline was a recognized thought leader in real estate investing as co-founder and chief investment officer of OneWall Communities. Previously, he led global consulting and financial training engagements with his own firm and partners after having spearheaded more than $20B of private equity and M&A transactions at Fortress and Merrill Lynch. Kline is a proud graduate of the Schreyer Honors College, Smeal College of Business, and Liberal Arts School at Pennsylvania State University, where he graduated with honors and two degrees in 4 years (BS in finance and BA in economics). While there, he co-founded the Nittany Lion Fund, marking a significant milestone as the first multimillion-dollar undergraduate student-managed hedge fund in the United States.

‍

Heather Koshinsky, PhD, serves as chair of the Bio+Health Track at Berkeley SkyDeck, UC Berkeley’s premier startup accelerator supporting the intersection of biology, healthcare, and technology. She is also the vice president of innovation and brand integrity at LevGo, which develops and manufactures laboratory consumables in China, the European Union, and the United States, with global distribution. As a serial entrepreneur, she has previously co-founded four successful startups. Notably, she was the co-founder and CEO at Investigen, which receives royalty revenue for its IP, and co-founder and CSO at Eureka Genomics, which developed Eureka Genotyping that Thermo Fisher Scientific now sells internationally.

Dr. Koshinsky is a member of several incubators and accelerators located in the United States and Canada, and is/has been an advisor and/or board member to startups located in Poland, China, Taiwan, Philippines, India, the United Kingdom, Australia, the United States, and Canada, covering fields including novel and repurposed drugs, medical devices and diagnostics, vaccines, bioreactors, remote sensing in agriculture, low-light imaging chips, and big data analysis software for single-cell immunogenetics. A grant reviewer for over 20 years, an inventor on multiple patent families, and author of numerous papers, Dr. Koshinsky earned her PhD in microbiology from the University of Saskatchewan and certificates in business administration and marketing from UC Berkeley Extension.

Rebecca Krupenevich, PhD, is a program officer in the Office of Data Resources and Analytics within the National Institute on Aging's Division of Behavioral and Social Research (BSR), where she works on initiatives related to AI infrastructure, data sharing, and public-private partnerships. Before joining BSR, she was an American Association for the Advancement of Science (AAAS) Science & Technology Policy fellow.

Dr. Krupenevich completed her PhD in kinesiology at the University of Maryland and postdoctoral training in biomedical engineering at the University of North Carolina at Chapel Hill. She also spent nearly 4 years as a graduate research assistant in the biomechanics lab at Walter Reed National Military Medical Center.

‍

Lyne Landry is a seasoned private equity investor and impact investment architect whose career spans continents and capital stacks. As co-founder of AgeTech Capital, she launched a next-generation investment firm focused on the trillion-dollar opportunity at the intersection of aging, AI, and purpose. Here, she is focused on building a firm that will reimagine aging as a source of resilience and value—deploying data-driven capital, scaling world-class solutions, and building a cross-sector movement that makes longevity work for all.

From leading $300M+ M&A transactions to structuring multi-fund platforms, she has consistently fused fiduciary discipline with a bold vision for systems change. Previously, at ThirdWay Partners, she helped build the firm from inception into a 45-person platform managing three funds. Known for building strong teams and operational foundations, Landry delivers strong financial returns pairing sharp investment strategies with a long-term view on how capital can accelerate impact at scale.

Rose Maria Li, PhD, MBA, is the president and CEO of Rose Li and Associates, Inc. and co-principal investigator of the a2 Collective Coordinating Center. The U.S. Small Business Administration named Dr. Li the 2024 Small Business Person of the Year for Maryland. She was also honored in 2024 to receive small business leadership awards from the International Leadership Foundation and the Montgomery County Chamber of Commerce. Since 2016, she has served by appointment of the governor as chairperson of the Maryland Commission on Aging. By appointment of the governor, she also served on the Maryland State Board of Education (2016–2021).

Prior to founding RLA, Dr. Li served the National Institutes of Health (NIH) in leadership roles, including as senior policy advisor to the NIH Office of Extramural Research, special assistant for policy development with the NIH Office of Communication and Public Liaison, chief of the Population and Social Processes Branch within the National Institute on Aging Division of Behavioral and Social Research, and health scientist administrator with the Eunice Kennedy Shriver National Institute of Child Health and Human Development. She earned her BA in economics and MBA in finance and international business, both from the University of Chicago, and her PhD from Princeton University in public and international affairs, with a concentration in population policy. She completed postdoctoral research in demography, epidemiology, and economics of aging in Asia at the University of Michigan, Ann Arbor.

Shari Ling, MD, serves in the Center for Clinical Standards and Quality, responsible for assisting the Centers for Medicare & Medicaid Services (CMS) chief medical officer in the agency’s pursuit of higher quality health care, healthier populations, and lower cost through quality improvement. Her clinical focus and scientific interest are centered on the care of persons with dementia, multiple chronic conditions, and functional limitations. In addition to a clinician leadership role across CMS, Dr. Ling has represented CMS on several HHS committees and workgroups, including the National Alzheimer’s Project Act, Healthy People, Behavioral and Mental Health, Healthcare Associated Infections, the National Strategy to Combat Antimicrobial Resistance, and the Scientific Integrity Council. She also serves on the Visioning Committee for the National Institute on Aging (NIA)-funded Coordinating Center on the Economics of Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias: Prevention, Treatment, and Care led by the National Bureau of Economic Research.

Dr. Ling is an internist and rheumatologist who received her medical training at Georgetown University School of Medicine. Prior to her medical training, Dr. Ling earned her master’s degree in gerontology from the Leonard Davis School at the University of Southern California and subsequently served as the co-director of clinical services with the Andrus Older Adult Counseling Center. She completed geriatric medicine studies at Johns Hopkins University, where she remained on faculty for 5 years, after which she joined the Intramural Research Program as a staff clinician at NIA for 8 years focused on human aging and age-associated chronic diseases with attention to musculoskeletal conditions and mobility function. Dr. Ling serves as a part-time faculty member in the Division of Geriatric Medicine and Gerontology at Johns Hopkins University School of Medicine, and in the Division of Rheumatology, Allergy and Clinical Immunology at the University of Maryland. She volunteers at the Veterans Administration Medical Center in Baltimore.

‍

Stephen C. Liu, MBA, serves as managing director of strategic partnerships for the a2 Collective Coordinating Center. He has more than 25 years of experience leading go-to-market, digital infrastructure, strategic partnerships, and innovation initiatives across early-stage startups, global corporations, and nonprofit ventures. He helped establish the a2 Collective’s national brand, outreach strategy, and digital infrastructure from the ground up. He also has led business development and partnership with venture capital, accelerators, and industry partners (e.g., AWS Activate).

‍

Kat Mackenzie, MBA, MPH, is director of discovery and strategic partnerships for the future of healthcare at Humana. Mackenzie is a strategic and creative healthcare leader with over 20 years of experience in growth, global market product design and implementation, organizational change management, and transformation projects. She previously guided the Innovation, Research, and Development team focused on building the pipeline for future growth at Humana Military, as well as served as strategic advisor to the chief medical officer on the development and advancement of the Humana Military Clinical Quality Enablement & Strategy.

Prior to joining Humana, Mackenzie successively held positions as director for emerging markets, strategic initiatives, and corporate strategy and growth at Beacon Health Options. Mackenzie completed her MBA with a focus in health sector management and MPH with a focus on health policy management at Boston University.

Jesse Mastrangelo, MSc, combines experience at the intersection of healthcare innovation, venture investment, and early-stage company development. As program manager at the Centre for Aging + Brain Health Innovation (CABHI), he leads their investment programs, supporting companies across health systems, longevity innovation, and life science. CABHI invests in healthtech, biotech, and fintech companies seeking to help older adults age with purpose, fulfillment, and dignity. As a core member of CABHI’s investment team, Mastrangelo has helped scale the organization’s investment portfolio to include over 100 companies as one of Canada's most active early-stage investors. He is also a lecturer in McMaster University's Faculty of Health Sciences, focusing on biomedical innovation.

Desh Mohan, MD, is co-founder and CMO of Koda Health, a digital health company building AI-powered infrastructure to support serious illness care planning at scale. He is a practicing internal medicine physician and hospitalist who has taken care of patients across the country for over a decade. He leads Koda’s clinical strategy, bringing together his background in medicine and digital health to ensure the platform fits seamlessly into real-world care. Today, Koda Health supports over 1 million patients through partnerships with organizations including Cigna, Privia Health, Memorial Hermann, and Houston Methodist.

Dr. Mohan earned his BS from MIT and his MD from UT Southwestern, and completed his internal medicine residency at Baylor College of Medicine. Along the way, he also worked on healthcare infrastructure projects in Tanzania, Haiti, and India—formative experiences that continue to shape his commitment to building systems rooted in dignity, empathy, and access.

‍

Michael A. Morgan, PhD, is a project manager and emerging science and technology advisor at the U.S. Food and Drug Administration, where he works in the Office of Regulatory and Emerging Science, Office of the Chief Scientist, Office of the Commissioner. Currently, Dr. Morgan co-leads a team of 50 experts from across FDA developing Elsa, FDA’s first enterprise generative AI chatbot. To date, over 70% of staff have voluntarily used the tool. He also serves as a Commissioner's Office representative to the FDA AI Internal Council, FDA's final decision-making body for internal AI policies and guidelines.

Previously, Dr. Morgan served on detail at the Department of Health and Human Services (HHS), where he co-led the evaluation and analysis of over 500 HHS AI use cases and provided technical and business expertise to guide HHS leadership in acquiring cutting-edge AI solutions, platforms, and environments. Before his HHS detail, Dr. Morgan developed a novel AI horizon scanning tool at FDA to identify emerging health-related science and technologies and forecast their potential regulatory impact. The tool was adopted by the Office of Personnel Management.

Dr. Morgan completed a postdoctoral fellowship at the U.S. Naval Research Laboratory and received his graduate degree from the University of Maryland, College Park, and his undergraduate degree from Syracuse University, both in biochemistry.

Mahesh Narayanan, MS, is the managing partner of Neuvation Ventures, an impact investment fund responsible for identifying and investing in early-stage companies, research, and ideas in the brain health sector. He is also the co-founder of MatchPlay, a venture capital firm that brings together strategic advisory, investment, and operational expertise to help organizations accelerate growth. With deep experience in entrepreneurship, venture building, and leadership, he works closely with founders and teams to translate ideas into sustainable, high-impact ventures.

Narayanan is an experienced investor and accelerator director with over 15 years in biotechnology and a founder of multiple companies in life sciences and technology with two successful exits. He has mentored 100+ startup companies, with focus in brain health and other deep tech innovations.

Hon Pak, MD, MBA, is a seasoned corporate physician executive with more than 25 years of healthcare strategic leadership in health information technology across both the public and private sectors. Dr. Pak is a change agent and has a proven track record in steering sustainable, profitable rapid growth and value creation in small and large organizations through his vision and team-based leadership. He is a problem solver and has also led several innovative healthcare companies/organizations through many operational and strategic transformations. He has also served as president and on the board of directors for several public and private organizations and is internationally recognized for his expertise in telemedicine, healthcare, and healthcare IT. Over the last 12 years, Dr. Pak has performed in numerous senior leadership roles providing strategic business development and capture support in both the commercial and federal healthcare sectors.

‍

Kunal Parikh, PhD, is an assistant professor at the Johns Hopkins University (JHU) School of Medicine in the divisions of glaucoma and nanomedicine at the Wilmer Eye Institute and at the Center for Bioengineering Innovation and Design within the JHU Department of Biomedical Engineering. Dr. Parikh leads a translational, R01-funded, interdisciplinary lab of engineers, scientists, and clinicians working together to create and translate novel biomedical solutions to alleviate human suffering at scale. His research program utilizes biodesign and insight-informed innovation methodologies to develop digital health technologies, surgical instruments, medical devices, multi-functional biomaterials, and therapeutics that can be readily scaled and adopted into clinical practice to enable access to care, improve treatment outcomes, and prevent post-operative complications. Several of his laboratory’s inventions have been licensed to industry or formed the basis for startup companies (Eyedea Medical, Cove Therapeutics, Samata Therapeutics, Visilant), including multiple commercial products.

Previously, Dr. Parikh built and served as the executive director of the Social Innovation Lab at JHU, where he advised and funded mission-driven entrepreneurs. Prior to arriving in Baltimore, he was the founding CEO of Core Quantum Technologies, a venture-backed biotechnology company developing superior imaging and detection reagents. Dr. Parikh earned his PhD in biomedical engineering at JHU where he was a Roche/ARCS Scholar and National Science Foundation Graduate Research Fellow.

Nick Patel has helped build an organization prepared to bring cutting-edge technology solutions to the senior living industry and beyond. With more than 20 years of experience with Fortune 500 companies across multiple business sectors, Patel has a deep understanding of strategic planning, finance, operations, and sales management in domestic and international markets.

Phillip Phan, PhD, is the Alonzo and Virginia Decker Professor of Strategy and Entrepreneurship at Johns Hopkins Carey Business School, a professor in the Division of Geriatric Medicine and Gerontology at Johns Hopkins Medicine, and a core faculty member at the Armstrong Institute for Patient Safety and Quality. At JH AITC, Dr. Phan serves as co-principal investigator and Networking and Mentoring Core director. An author of more than 300 peer-reviewed research articles and author/editor of 13 scholarly books, Dr. Phan’s academic and professional work focuses on the commercialization of biomedical technology and health services research, technological innovations that emphasize patient safety, quality, and biomedicine, as well as AI applications for patient care.

Rosalind W. Picard, ScD, is the Grover M. Hermann Professor in Health Sciences and Technology and MIT’s Media Lab, founder and director of the Affective Computing research group at the MIT Media Lab, founding faculty chair of MIT's MindHandHeart Initiative, and a faculty member of the MIT Center for Neurobiological Engineering. She has co-founded two companies: Affectiva (now part of Smart Eye), providing emotion AI technologies now used by more than 25% of the Global Fortune 500, and Empatica, providing wearable sensors and analytics to improve health. Starting from inventions by Dr. Picard and her team, Empatica created the first AI-based smart watch cleared by FDA (in neurology for monitoring seizures), helping alert to bring potentially life-saving help for people with epilepsy.

Dr. Picard is an active inventor with patents including wearable and non-contact sensors, algorithms, and systems for sensing, recognizing, and responding respectfully to human affective information. She is a member of the National Academy of Inventors and the National Academy of Engineering, as well as a fellow of the Institute of Electrical and Electronics Engineers (IEEE), the Association for the Advancement of Affective Computing (AAAC), and the Association for Computing Machinery (ACM). She holds a bachelor's degree in electrical engineering with highest honors from the Georgia Institute of Technology, and master's and doctorate degrees, both in electrical engineering and computer science, from MIT. Prior to joining the MIT Media Lab faculty, Dr. Picard worked as a member of the technical staff at AT&T Bell Laboratories, where she designed VLSI chips optimized for signal processing and developed new image compression techniques.

‍

Kyle Rand is the co-founder and CEO of Rendever, an AgeTech company leveraging immersive technology to improve the lives of older adults. Under his leadership, Rendever has pioneered the use of virtual reality to reduce social isolation and support cognitive and emotional well-being across senior living communities and healthcare settings. As a pilot awardee with the MassAITC program, his research explores the ability to use RendeverFit®, a virtual reality fitness platform, to create a digital biomarker to remotely assess changes in physical and cognitive functions in order adults receiving physical therapy while aging in place. He is also PI on an STTR grant, in collaboration with RAND, that brings home health dementia caregivers into the design process of a virtual reality platform seeking to mitigate their work-related burden and social isolation by cultivating a virtual community of support.

Rand graduated with dual degrees in biomedical engineering and neuroscience from Duke University, and was a Pratt Research Fellow at the world-renowned Nicolelis Lab. Since joining the tech world, he has led the development of a niche research-based social network, created a crowdfunding platform for ecological conservation, and architected a grassroots initiative focused on increasing healthcare access in populations-in-need. He was named to Forbes 30 Under 30 in 2019 and Rendever was honored on the 2022 TIME list of 100 Most Influential Companies.

Rick Robinson has led teams building products and boosting startups at AARP’s Innovation Labs and the AgeTech Collaborative for 6 years. Prior to that he cofounded venture-backed and public companies, with two exits, and led product and content functions at AOL, Sprint, Politico, and National Geographic.

‍

Orit Rozenblatt-Rosen, PhD, is head of the Cell and Tissue Genomics Department and[KH2.1] co-leads foundational data for foundation models at Genentech. She also co-leads the Standards and Technology Working Group for the Human Cell Atlas. Dr. Rozenblatt-Rosen is a pioneer of single-cell genomics, especially in the context of human tissues. She is a strategic leader with extensive experience driving drug discovery and innovation at the intersection of genomics, biology, and AI. She is an expert in leveraging the “lab-in-the-loop” approach to identify novel targets, compounds, and biomarkers and is recognized for accelerating disease biology insights in oncology, neuroscience, and immunology through robust cross-functional collaboration.

Prior to joining Genentech, Dr. Rozenblatt-Rosen held scientific appointments in academia over a 20-year period, first at the Dana-Farber Cancer Institute and then at the Broad Institute of MIT and Harvard. She received her BSc and MSc degrees from Tel Aviv University, and PhD from the Weizmann Institute of Science. She conducted postdoctoral studies at the Weizmann Institute of Science and the Dana-Farber Cancer Institute.

Anindita (Annie) Saha is associate director for strategic initiatives for the Digital Health Center of Excellence (DHCoE) in the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (FDA) where she supports promoting innovation of digital health technologies, including those enabled by AI. She is also serving as the acting associate director for data science and AI policy at the FDA Center for Drug Evaluation and Research (CDER) to support the use of AI across the drug development lifecycle. Additionally, Saha helped incubate and continues to support to advance the science and adoption of patient input as evidence, including patient preference information (PPI) and clinical outcome assessments (COAs).

Previously, Saha was the director of the Partnerships team in CDRH where she oversaw a broad program portfolio, supporting several strategic partnership and regulatory science programs. Saha started at FDA as a researcher in the Office of Science and Engineering Laboratories in imaging display technologies. She has a BS in bioengineering and minor in history from the University of Pittsburgh.

Raghav Sehgal, PhD, is an associate research scientist in computational biology at Yale University and a scientific principal at Longevity Tech Fund, a venture capital firm that focuses on investing in companies that are innovating in the fields of AI, digital health, medical devices, and diagnostics. Dr. Sehgal is passionate about solving the mysteries of aging and extending healthy lifespans. He is developing machine learning and deep learning tools to analyze multi-omic and multi-modal data, and to answer questions about what biological systems drive aging, how we can measure them, and if we can reverse them. As part of his research, he built SYMPHONYAge a patented biomarker that can measure aging in 11 different organs from a single blood draw.

At Longevity Tech Fund, Dr. Sehgal provides expert advice on potential investment opportunities and helped raise their second fund by building strategies for future investments. He has 10 years of experience in applying data science and AI to the biomedical space as a scientist, engineer, product manager, team builder, academician, and entrepreneur. He completed his PhD at Yale University, is a Forbes 30 Under 30 honoree, and has received awards such as the Gruber Science Fellowship and Impetus Aging Grant.

‍

Russell H. Taylor, PhD, is a John C. Malone Professor in the Department of Computer Science at Johns Hopkins University (JHU) with secondary appointments in the Department of Mechanical Engineering and the School of Medicine’s Departments of Otolaryngology–Head and Neck Surgery, Radiology and Radiological Science, and Surgery. He has more than 50 years of professional experience in the fields of computer science, robotics, and computer-integrated interventional medicine. For more than a decade, he served as the director for JHU’s Laboratory for Computational Sensing and Robotics, one of the most technologically advanced robotics research centers worldwide and an international leader in the areas of medical robotics, autonomous systems, and bio-inspiration.

Dr. Taylor is also a member of JHU’s Malone Center for Engineering in Healthcare, Institute for Assured Autonomy, and Data Science and AI Institute. He is a member of the National Academy of Engineering and a fellow of the Institute of Electrical and Electronics Engineers (IEEE), the National Academy of Inventors, the American Institute for Medical and Biological Engineering (AIMBE), the Medical Image Computing and Computer Assisted Intervention (MICCAI) Society, and the Engineering School at the University of Tokyo. Prior to his appointment at JHU, he completed his PhD in computer science at Stanford University and subsequently served at IBM Research for nearly two decades, where he developed the AML robot programming language and held management roles in robot systems and technology, automation technology, and computer-assisted surgery.

‍

Alex Triantis, PhD, joined the Johns Hopkins Carey Business School in 2019. During his tenure, Dr. Triantis has led the revision or launch of a large suite of graduate degree programs, and Carey’s reputation for innovative interdisciplinary research and impactful outreach has been further enhanced through its unique positioning in the business of health and in AI, its eight new centers of excellence, and its high-profile events featuring corporate and government leaders in Baltimore and at the Johns Hopkins University Bloomberg Center in Washington, D.C.

Before joining Carey Business School, Dr. Triantis served as dean of the Robert H. Smith School of Business at the University of Maryland from 2013 to 2019, and chair of the finance department from 2006 to 2011. He previously served on the faculty at the University of Wisconsin and was a visiting scholar at MIT’s Sloan School of Management. An expert in the areas of corporate financial strategy and valuation, Triantis has published articles in numerous prestigious academic journals, served on several journal editorial boards, and has consulted and led training for many multinational corporations. Triantis received his PhD from Stanford University and his BASc and MEng degrees from the University of Toronto.

Randall Williams, MD, is a visionary and experienced physician, executive, digital health pioneer and serial entrepreneur, board member, founder, and CEO. He is currently the CEO of WellSaid AI, an industry leader in the rapidly emerging field of AgeTech. WellSaid AI’s mission is to support active, healthy aging by improving the early detection and support of individuals with cognitive or physical decline, social isolation, and related challenges to living independently.

Dr. Williams brings a unique breadth of healthcare clinical and executive leadership, market and operational experience, and insight. Following his medical training at the Johns Hopkins School of Medicine as a heart failure and transplant cardiologist, he was recruited to Northwestern University in Chicago. There, he built one of the first nationally recognized chronic care programs for heart failure and the organization’s care management infrastructure. In 2004, he launched his first healthcare technology startup, Pharos Innovations, a pioneer in the field of telehealth and remote patient monitoring. Dr. Williams has testified before and advised the U.S. Senate, Congressional Budget Office, and both the George W. Bush and Obama administrations on healthcare delivery system reform, as well as helped design the Center for Medicare and Medicaid Innovation (CMMI) at the Centers for Medicare & Medicaid Services (CMS).

David Yonce, MS, MBA, is the CEO of Cogwear, a brain technology company that improves health, peace, and performance through its comfortable, wearable technology that provides clinical-grade insights into brain health. He is a medical device and technology executive who has positioned companies for double-digit growth and acquisition, helped deliver over 50 new products to market, and has received 54 patents.

With more than 25 years in the medical device space, including 20 of those in a management or executive capacity, he has held diverse roles across R&D, operations, marketing, strategy, and sales at companies such as Boston Scientific, AMS, and DSM Biomedical. He also serves on the advisory boards of several companies and counsels industry advocacy groups and multiple public seed fund initiatives. Yonce earned a BS in Electrical Engineering from Cornell University, holds an MS in Electrical Engineering from the University of Maryland, and graduated with honors with an MBA from the University of Chicago Booth School of Business.

Alex Zhavoronkov, PhD, is the founder, CEO,and CBO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative AI and robotics platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative AI and reinforcement learning for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data. Under his leadership, Insilico raised over $530 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened R&D centers in 8 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated more than 22 preclinical candidates, 10 of which reached clinical stage, and one program with a novel target and novel molecule completed Phase IIa in idiopathic pulmonary fibrosis with favorable safety, tolerability, and encouraging dose-dependent efficacy.

Since 2012, Dr. Zhavoronkov has published over 310 peer-reviewed research papers, with over 30 papers in the field of generative adversarial networks, generative reinforcement learning, and multi-modal transformers, and three books. He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, and Frontiers in Genetics, and founded and co-chairs the annual Aging Research and Drug Discovery Meeting. Dr. Zhavoronkov is the adjunct professor of AI at the Buck Institute for Research on Aging.

‍